ArticleLeukemia2024
Iron overload induces dysplastic erythropoiesis and features of myelodysplasia in Nrf2-deficient mice.
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 5 citations in OpenAlex.
- CD163Biomarker research · 2026Article
- Loss of Hfe impairs hematopoietic stem and progenitor cell function.Blood. Red cells & iron · 2026Article
- High serum ferritin is associated with genetic instability in myelodysplastic neoplasms.Journal of cancer research and clinical oncology · 2026Article
- Systematic Review of Non-Coding Genomic Variants in Globin and Non-Globin Clusters and Their Impact on Phenotypic Severity in Thalassemia and Sickle Cell Disease.Journal of clinical medicine · 2026Review
- Risk factor analysis and prediction model construction for delayed erythroid hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation: a single-center retrospective study.Frontiers in oncology · 2026Article
- Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study.European journal of medical research · 2025Article
- Evaluated NSUN3 in reticulocytes from HbH-CS disease that reflects cellular stress in erythroblasts.Annals of hematology · 2025Article
- Ferroptosis as an emerging target in sickle cell disease.Current research in toxicology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Funding
Abstract
Iron overload (IOL) is hypothesized to contribute to dysplastic erythropoiesis. Several conditions, including myelodysplastic syndrome, thalassemia and sickle cell anemia, are characterized by ineffective erythropoiesis and IOL. Iron is pro-oxidant and may participate in the pathophysiology of these conditions by increasing genomic instability and altering the microenvironment. There is, however, lack of in vivo evidence demonstrating a role of IOL and oxidative damage in dysplastic erythropoiesis. NRF2 transcription factor is the master regulator of antioxidant defenses, playing a crucial role in the cellular response to IOL in the liver. Here, we crossed Nrf2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.